Fulcrum Therapeutics (FULC)

Executive Summary

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for genetically defined rare diseases. Its lead program, losmapimod for facioscapulohumeral muscular dystrophy (FSHD), failed in a Phase 3 trial (NCT05397470) which was terminated in 2024. Despite this setback, the company continues to pursue its pipeline, leveraging its gene expression modulation platform. The company's market cap is approximately $505 million as of early 2026, reflecting investor caution given the FSHD program's failure and early stage of other candidates. The company's primary remaining asset is pociredir (formerly FTX-6058), a potential treatment for sickle cell disease (SCD). Pociredir is being evaluated in a Phase 1/2 program. A Phase 1 trial (NCT07431398) in SCD patients is expected to complete in April 2026, with top-line data likely in the second quarter. A Phase 2 trial (NCT07401823) began enrollment in March 2026 and will run through 2030. The company has no approved products and its future hinges on pociredir's clinical success. With the FSHD program discontinued, Fulcrum must demonstrate proof-of-concept in SCD to regain investor confidence.

Upcoming Catalysts (preview)

• Q2 2026Pociredir Phase 1 SCD top-line data readout70% success